Cargando…
First-Line Treatment Options for PD-L1–Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
BACKGROUND: First-line treatment strategies for programmed death-ligand 1 (PD-L1) negative non-small cell lung cancer (NSCLC) patients include chemotherapy and combination with anti-angiogenesis drugs and/or immune checkpoint inhibitor. We conducted a Bayesian network meta-analysis to evaluate the e...
Autores principales: | Peng, Ling, Liang, Wen-Hua, Mu, De-Guang, Xu, Song, Hong, Shao-Dong, Stebbing, Justin, Liang, Fei, Xia, Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261279/ https://www.ncbi.nlm.nih.gov/pubmed/34249693 http://dx.doi.org/10.3389/fonc.2021.657545 |
Ejemplares similares
-
Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
por: Peng, Ling, et al.
Publicado: (2021) -
Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
por: Peng, Ling, et al.
Publicado: (2021) -
First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
por: Bulbul, Ajaz, et al.
Publicado: (2018) -
The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
por: Yang, Hui, et al.
Publicado: (2020) -
Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
por: Lu, Hong-Rui, et al.
Publicado: (2023)